Stay updated with breaking news from Life Core. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Adding Keytruda to EBRT and chemotherapy, followed by brachytherapy, improved progression-free survival in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
The addition of pembrolizumab to external beam radiotherapy and concurrent chemotherapy, followed by brachytherapy, resulted in statistically significant and clinically meaningful improvements in progression-free survival when compared with placebo plus EBRT/chemoradiotherapy/brachytherapy in patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Patient-reported outcomes with fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer reflected the regimen’s favorable risk-benefit profile in the phase 3 DESTINY-Breast02 trial, according to findings presented during the 2023 ESMO Breast Cancer Annual Congress.
MARION THURS., APRIL 27, NOON- 6 PM Sign in sheet out at 11 AM FRI., APRIL 28, NOON- 6 PM SAT., APRIL 29, 10 AM- 2 PM View photos online @http://www.shoptopdrawer.com or Estatesales.net 4310 Snowgoose Dr. GREAT SALE, QUALITY ITEMS! Drexel dining table/6 chairs, buffet, hutch Pr. Century brocade
Patients who received trastuzumab deruxtecan (T-DXd) for human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer reported that the treatment maintained their quality of life (QoL) compared to conventional chemotherapy, according to results presented today by researchers from The University of Texas MD Anderson Cancer Center at the European Society for Medical Oncology Congress 2022.